Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma (Hnscc): Post Hoc Analyses of Treatment Options from the Phase Iii Keynote-040 Trial
AuthID
P-00Q-93T
P-00Q-93T
© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service